Smith & Nephew agreed to fork over $1.7 billion for ArthroCare, a Texas device company that specializes in sports medicine joint repair and recently settled long-standing federal fraud charges in the U.S.
CRO conglomerate inVentiv Health has extended its deal with Swedish outfit NeuroVive Pharmaceutical, and the contract researcher says its ability to tailor its platform to developers of all sizes make it an ideal partner for drugmakers on the come-up.
The U.K.'s Ergomed takes a more hands-on approach to contract development than many CROs, and the company has inked another risk-sharing partnership, teaming up with Spain's Ferrer to progress an insomnia treatment.
Right now, any biotech that might have the key to new and better checkpoint immunotherapies is the belle of the deal-making ball. And Belgium's Ablynx--which has been lining up pharma giants for a string of 9-figure deals to develop next-gen antibodies--just parlayed its tech know-how into a heavily backloaded $2.3 billion discovery deal with Merck, arguably the leader in the field.
Japanese medical device giant Terumo has inked a deal with CareFusion to jump-start U.S. sales of its IV catheters, counting on its partner's experience and share of the market to boost its stateside revenue.
San Diego's Epic Sciences is working to expand access to its novel cancer diagnostic, joining forces with global giant LabCorp to make the test available to European drug developers.
When AstraZeneca CEO Pascal Soriot unveiled the company's new R&D strategy a little less than a year ago, the antibiotics research field was downgraded in the revamp--part of a general retreat by the industry as superbugs presented an ever-growing threat around the world. But the pharma heavyweight didn't abandon antibiotics.
Varian Medical Systems has reupped a three-year deal with Toshiba Medical Systems to supply medical imaging components. The new agreement is worth about $515 million, the two companies say in a news release today.
Clinical trial software outfits Datatrak and Clinverse have joined forces to provide what they say is the industry's first end-to-end technology for financing studies.
The New York City-based Alzheimer's Drug Discovery Foundation and the U.K.'s Alzheimer's Society are collaborating to launch a $3 million initiative that will provide funding for research in Alzheimer's disease and related dementias.